GeoVax Labs Inc (GOVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH56885D
- Pages: 60
- November 2018
- Total Views:1177
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company's vaccine development programs focus on HIV, Zika virus and hemorrhagic fever viruses (Ebola, Marburg, Lassa fever) and for cancer immunotherapy. Its advanced vaccines under development act against the clade B subtype of the HIV virus and clade C subtype. GeoVax developed its proprietary vaccine technology in collaboration with the U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.
GeoVax Labs Inc (GOVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
GeoVax Labs and PharmaJet Enter into Partnership 13
Geovax Labs and Emory University Enter into Partnership 14
GeoVax Labs Enters into Agreement with CaroGen 15
GeoVax Labs Enters into Agreement with Vaxeal 16
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17
GeoVax Labs Enters into Partnership with American Gene Technologies 18
GeoVax Labs Research Agreement with Georgia State University Research Foundation 19
GeoVax Labs Enters into Research Agreement with Burnet Institute 20
GeoVax Labs Enters into Co-Development Agreement with ViaMune 21
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22
GeoVax Labs Enters into R&D Agreement with USAMRIID 23
GeoVax Labs Enters into Research Agreement with University of Georgia 24
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26
Licensing Agreements 27
GeoVax Labs Enters into Licensing Agreement with Valneva 27
Equity Offering 28
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29
GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30
GeoVax Labs Raises USD6 Million in Private Placement 31
GeoVax Labs Completes Private Placement Of Shares For USD 1.6 Million 32
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For USD 2.2 Million 33
GeoVax Completes Second Tranche Of Private Placement Of Units For USD 0.25 Million 34
GeoVax Labs Inc-Key Competitors 35
GeoVax Labs Inc-Key Employees 36
GeoVax Labs Inc-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 07, 2018: GeoVax reports 2018 second quarter financial results and provides corporate update 38
May 03, 2018: GeoVax Reports 2018 First Quarter Financial Results and Development Program Updates 40
Mar 23, 2018: GeoVax Announces 2017 Year-End Financial Results 42
Nov 09, 2017: GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates 43
Aug 07, 2017: GeoVax Reports 2017 Second Quarter Financial Results Results and Provides Corporate Update 45
May 08, 2017: GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates 47
Mar 24, 2017: GeoVax Reports 2016 Year-End Financial Results 48
Corporate Communications 49
Aug 14, 2018: GeoVax names David Dodd as Chairman, President and Chief Executive Officer 49
Product News 50
10/09/2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress 50
08/30/2017: GeoVax Presents Preliminary Data for Cancer Vaccine 51
04/03/2017: GeoVax Awarded USD 658,000 NIH Grant for its HIV Vaccine Program 52
01/16/2018: GeoVax Publishes Ebola Vaccine Study Results in Nature's Scientific Reports 53
Clinical Trials 54
Jan 23, 2017: GeoVax Announces Initiation of HIV Human Clinical Trial 54
Other Significant Developments 55
Mar 28, 2018: GeoVax Provides Vaccine Development Update 55
Mar 27, 2017: GeoVax Reports on Vaccine Development Progress 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
List Of Figure
List of Figures
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GeoVax Labs and PharmaJet Enter into Partnership 13
Geovax Labs and Emory University Enter into Partnership 14
GeoVax Labs Enters into Agreement with CaroGen 15
GeoVax Labs Enters into Agreement with Vaxeal 16
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17
GeoVax Labs Enters into Partnership with American Gene Technologies 18
GeoVax Labs Research Agreement with Georgia State University Research Foundation 19
GeoVax Labs Enters into Research Agreement with Burnet Institute 20
GeoVax Labs Enters into Co-Development Agreement with ViaMune 21
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22
GeoVax Labs Enters into R&D Agreement with USAMRIID 23
GeoVax Labs Enters into Research Agreement with University of Georgia 24
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26
GeoVax Labs Enters into Licensing Agreement with Valneva 27
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29
GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30
GeoVax Labs Raises USD6 Million in Private Placement 31
GeoVax Labs Completes Private Placement Of Shares For USD 1.6 Million 32
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For USD 2.2 Million 33
GeoVax Completes Second Tranche Of Private Placement Of Units For USD 0.25 Million 34
GeoVax Labs Inc, Key Competitors 35
GeoVax Labs Inc, Key Employees 36
GeoVax Labs Inc, Subsidiaries 37
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
GeoVax Labs Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company's vaccine development programs focus on HIV, Zika virus and hemorrhagic fever viruses (Ebola, Marburg, Lassa fever) and for cancer immunotherapy. Its advanced vaccines under development act against the clade B subtype of the HIV virus and clade C subtype. GeoVax developed its proprietary vaccine technology in collaboration with the U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.
GeoVax Labs Inc (GOVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
GeoVax Labs and PharmaJet Enter into Partnership 13
Geovax Labs and Emory University Enter into Partnership 14
GeoVax Labs Enters into Agreement with CaroGen 15
GeoVax Labs Enters into Agreement with Vaxeal 16
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17
GeoVax Labs Enters into Partnership with American Gene Technologies 18
GeoVax Labs Research Agreement with Georgia State University Research Foundation 19
GeoVax Labs Enters into Research Agreement with Burnet Institute 20
GeoVax Labs Enters into Co-Development Agreement with ViaMune 21
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22
GeoVax Labs Enters into R&D Agreement with USAMRIID 23
GeoVax Labs Enters into Research Agreement with University of Georgia 24
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26
Licensing Agreements 27
GeoVax Labs Enters into Licensing Agreement with Valneva 27
Equity Offering 28
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29
GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30
GeoVax Labs Raises USD6 Million in Private Placement 31
GeoVax Labs Completes Private Placement Of Shares For USD 1.6 Million 32
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For USD 2.2 Million 33
GeoVax Completes Second Tranche Of Private Placement Of Units For USD 0.25 Million 34
GeoVax Labs Inc-Key Competitors 35
GeoVax Labs Inc-Key Employees 36
GeoVax Labs Inc-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 07, 2018: GeoVax reports 2018 second quarter financial results and provides corporate update 38
May 03, 2018: GeoVax Reports 2018 First Quarter Financial Results and Development Program Updates 40
Mar 23, 2018: GeoVax Announces 2017 Year-End Financial Results 42
Nov 09, 2017: GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates 43
Aug 07, 2017: GeoVax Reports 2017 Second Quarter Financial Results Results and Provides Corporate Update 45
May 08, 2017: GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates 47
Mar 24, 2017: GeoVax Reports 2016 Year-End Financial Results 48
Corporate Communications 49
Aug 14, 2018: GeoVax names David Dodd as Chairman, President and Chief Executive Officer 49
Product News 50
10/09/2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress 50
08/30/2017: GeoVax Presents Preliminary Data for Cancer Vaccine 51
04/03/2017: GeoVax Awarded USD 658,000 NIH Grant for its HIV Vaccine Program 52
01/16/2018: GeoVax Publishes Ebola Vaccine Study Results in Nature's Scientific Reports 53
Clinical Trials 54
Jan 23, 2017: GeoVax Announces Initiation of HIV Human Clinical Trial 54
Other Significant Developments 55
Mar 28, 2018: GeoVax Provides Vaccine Development Update 55
Mar 27, 2017: GeoVax Reports on Vaccine Development Progress 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
List Of Figure
List of Figures
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GeoVax Labs and PharmaJet Enter into Partnership 13
Geovax Labs and Emory University Enter into Partnership 14
GeoVax Labs Enters into Agreement with CaroGen 15
GeoVax Labs Enters into Agreement with Vaxeal 16
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17
GeoVax Labs Enters into Partnership with American Gene Technologies 18
GeoVax Labs Research Agreement with Georgia State University Research Foundation 19
GeoVax Labs Enters into Research Agreement with Burnet Institute 20
GeoVax Labs Enters into Co-Development Agreement with ViaMune 21
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22
GeoVax Labs Enters into R&D Agreement with USAMRIID 23
GeoVax Labs Enters into Research Agreement with University of Georgia 24
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26
GeoVax Labs Enters into Licensing Agreement with Valneva 27
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29
GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30
GeoVax Labs Raises USD6 Million in Private Placement 31
GeoVax Labs Completes Private Placement Of Shares For USD 1.6 Million 32
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For USD 2.2 Million 33
GeoVax Completes Second Tranche Of Private Placement Of Units For USD 0.25 Million 34
GeoVax Labs Inc, Key Competitors 35
GeoVax Labs Inc, Key Employees 36
GeoVax Labs Inc, Subsidiaries 37
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
GeoVax Labs Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 99224 42855 
Related Reports
Page 157 | 
June 2021
Page 130 | December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020